OZEMPIC (SEMAGLUTIDE) FOR TYPE 2 DIABETES AND WEIGHT MANAGEMENT A SYSTEMATIC REVIEW OF REGULATORY APPROVAL PATHWAYS ACROSS COUNTRIES AND A META-ANALYSIS OF THE CLINICAL EVIDENCE

Abstract

Background: Semaglutide (Ozempic®, Rybelsus®, Wegovy®), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has received regulatory approvals across multiple jurisdictions for type 2 diabetes mellitus (T2DM) and chronic weight management. The clinical trial program underpinning these approvals provides an extensive evidence base in metabolic medicine. Objectives: To synthesise the clinical evidence for semaglutide on HbA1c reduction, body weight loss, and major adverse cardiovascular events (MACE), and to map the regulatory approval pathways across the FDA, EMA, PMDA, Health Canada, and TGA. Methods: PRISMA 2020-compliant systematic review with random-effects meta-analysis (DerSimonian–Laird method). A systematic literature search was conducted in PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane CENTRAL, PsycINFO, IEEE Xplore, ACM Digital Library, and relevant clinical-trial registries from database inception to September 9, 2026. Eligible studies: RCTs, systematic reviews, and meta-analyses reporting HbA1c, body weight, or cardiovascular outcomes in adults treated with semaglutide. Heterogeneity was assessed using I² and Q statistics. Publication bias was evaluated with Egger’s test and funnel-plot analysis. Results: From 1696 identified records, 20 reports met inclusion criteria. HbA1c: Pooled mean difference (MD) = −0.88% (95% CI −1.04 to −0.72; I² = 93.6%), favouring semaglutide over all comparators. Body weight: Pooled MD = −4.95 kg (95% CI −6.18 to −3.72; I² = 99.2%). With semaglutide 2.4 mg, weight loss reached −14.9% (STEP 1). MACE: Pooled hazard ratio (HR) = 0.79 (95% CI 0.72–0.87; I² = 0.0%), corresponding to a 21% relative risk reduction. Systolic blood pressure was reduced by 3–7 mmHg across trials. Regulatory approvals by the FDA (2017), EMA (2018), Health Canada (2018), TGA (2020), and PMDA (2018) were underpinned by the SUSTAIN (1–10), PIONEER (1–10), STEP (1–5), and SELECT trial program. Conclusion: Semaglutide produces clinically meaningful, consistent, and durable improvements in glycaemic control, body weight, and cardiovascular outcomes. The comprehensive evidence base across diverse populations and formulations supports its multifaceted role in metabolic disease management.